Tonix Pharmaceuticals Receives First Contract Payment From U.S. Department Of Defense For Accelerated Development Of Broad-Spectrum Antivirals With The Defense Threat Reduction Agency; The Previously Announced Award From DTRA Is For Up To $34M Over 5-Years
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has received its first contract payment from the U.S. Department of Defense for the development of broad-spectrum antivirals. The contract, awarded by the Defense Threat Reduction Agency, is valued at up to $34 million over five years.
October 17, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has secured its first payment from a $34 million contract with the U.S. Department of Defense for antiviral development, enhancing its revenue stream and partnership with a government agency.
The receipt of the first payment from a significant $34 million contract with the U.S. Department of Defense is a positive development for Tonix Pharmaceuticals. It not only provides a new revenue stream but also strengthens its partnership with a major government agency, which could enhance its credibility and future business prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100